Portfolio news

argenx raises approximately $100 million gross proceeds with NASDAQ IPO

Date: 18/05/2017

18 May 2017, Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX, Nasdaq: ARGX) announced today the pricing of its initial public offering in the United States (the “Offering”) with anticipated gross proceeds totalling approximately $100 million from the sale of 5,865,000 American Depository Shares (“ADSs”), at a price to the public of $17.00 per ADS. (more…)

NutriLeads closes series A round to advance the development of its lead nutritional ingredient supporting immune function

Date: 29/03/2017

29 March 2017, Wageningen, The Netherlands -Dutch nutritional health ingredients startup NUTRILEADS B.V. today announces the successful closing of a Series A financing round with existing shareholders DSM VENTURING, PPM OOST, SHIFT INVEST and THUJA CAPITAL. (more…)

Argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoimmune diseases

Date: 21/03/2017

21 March 2017, Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced that it has entered into a new collaboration with Broteio Pharma B.V. to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. (more…)

Cristal Therapeutics successfully closes €12.8 million financing round

Date: 19/01/2017

19 January 2016, Maastricht, The Netherlands – Cristal Therapeutics today announced the closing of a €12.8 million financing round. The financing comes from a consortium headed by Dutch oncology investor Aglaia BioMedical Ventures and Belgian DROIA Oncology Ventures (more…)

Newspaper articles: Hemics install first Handscan device in Dutch hospital

Date: 10/01/2017

10 January 2017, Eindhoven, The Netherlands – The regional Dutch newspaper Eindhovens Dagblad reported on Hemics installing a first Handscan device in a major Dutch hospital.  (more…)

Thuja Capital leads series A investment round in Indigo Diabetes

Date: 20/12/2016

20 December 2016, Utrecht (NL) and Ghent (B) — Indigo Diabetes nv (Indigo), a spin-off from Ghent University (UGent) and imec, today announces the successful closure of a 7 million Euros series-A financing round. The funding is provided by an international investment syndicate led by Thuja Capital Healthcare Fund II (The Netherlands) (more…)

argenx launches Phase I/II study of ARGX-110 in combination with azacitidine in newly diagnosed AML patients

Date: 15/12/2016

15 December 2016, Breda, the Netherlands / Ghent, Belgium – argenx today announced the initiation of a Phase I/II clinical trial of ARGX-110 in combination with azacitidine in newly diagnosed, elderly acute myeloid leukemia (AML) patients. (more…)

Cristal Therapeutics and iTeos Therapeutics announce strategic partnership

Date: 07/12/2016

7 December 2016, Maastricht, The Netherlands and Gosselies, Belgium –  Cristal Therapeutics and iTeos Therapeutics today announced a strategic partnership for the discovery, development and commercialization of optimized immuno anti-cancer drug candidates, (more…)

NutriLeads announces positive outcome of proof-of-concept study in humans

Date: 24/11/2016

24 November 2016, Wageningen, The Netherlands. NutriLeads B.V. today announces the positive outcome of a proof of concept study in humans demonstrating that its lead ingredient IMPP-1 is safe, well tolerated and supports immune function in humans. (more…)

Nutrileads wins prestigious Eurostars grant

Date: 21/11/2016

21 November 2016, Wageningen, The Netherlands. NutriLeads B.V., a Dutch Nutrition & Health startup has won a prestigious Eurostars grant to support the development of its lead ingredient IMPP-1 for application in medical foods. Nutrileads (as consortium leader) and 4 partners from the Netherlands, Germany and Finland have been awarded a € 2 million (more…)

NightBalance closes EUR 12.5 million Series B financing to support commercial rollout in Europe and enter the U.S. market with its innovative sleep apnea device

Date: 05/07/2016

5 July 2016, Delft, the Netherlands – NightBalance BV, a leading innovator of obstructive sleep apnea (OSA) technology, today announced the completion of a EUR 12.5 million Series B financing round led by INKEF Capital and Gilde Healthcare Partners. Existing investors Thuja Capital, Health Innovation Fund, and Van Herk Ventures also participated. (more…)

argenx announces initial results from Phase 1 multiple ascending dose study of ARGX-113 in healthy volunteers

Date: 30/06/2016

30 June 2016 – Breda, the Netherlands / Ghent, Belgium – argenx, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced initial results from its Phase 1 multiple ascending dose (MAD) study of ARGX-113 (more…)

argenx announces efficacy and expanded safety data from Phase 1 trial of ARGX-111

Date: 03/06/2016

3 June 2016, Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced data published in conjunction with the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting (Chicago, USA) (more…)

NutriLeads announces collaboration with DSM Nutritional Products

Date: 26/05/2016

26 May 2016, Wageningen, The Netherlands – Dutch nutritional health ingredients startup NutriLeads B.V. announces the signing of a collaboration agreement with DSM Nutritional Products for the further development of its lead ingredient. (more…)

Cristal Therapeutics announces appointment of Edwin Klumper as Chief Medical Officer

Date: 28/04/2016

28 April 2016, Maastricht, The Netherlands – Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform, today announced the appointment of Edwin Klumper as Chief Medical Officer. (more…)

argenx and AbbVie to collaborate on ARGX-115 against novel immuno-oncology target

Date: 21/04/2016

21 April 2016 — AbbVie (NYSE:ABBV), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune (more…)

Argenx’s partner Bird Rock Bio demonstrates potential for gerilimzumab, a novel SIMPLE antibody™ against IL-6 to treat rheumatoid arthritis

Date: 16/03/2016

16 March 2016 – Breda, The Netherlands / Ghent, Belgium – argenx N.V. (Euronext Brussels: ARGX) today reported that its partner Bird Rock Bio (formerly RuiYi) has announced that gerilimzumab, a novel SIMPLE Antibody™ neutralizing the IL-6 cytokine, has demonstrated safety and pharmacokinetics that support low, infrequent dosing and the potential for favorable pricing. (more…)

argenx receives milestone payment in LEO Pharma collaboration

Date: 02/02/2016

2 February 2016, Breda, The Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced it has received a milestone payment in connection with its collaboration with LEO Pharma. The companies have selected a lead cell line for manufacture of the licensed SIMPLE AntibodyTM candidate, in development for the treatment of inflammatory skin conditions. (more…)

argenx announces initial results from a Phase 1 single ascending dose study of ARGX-113 in healthy volunteers

Date: 06/01/2016

6 January 2016, Breda, The Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced that it has completed the dose-escalation part of a Phase 1 study of ARGX-113. (more…)

arGEN-X completes first dosing of ARGX-113 for severe autoimmune disorders

Date: 22/10/2015

22 October 2015, Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) today announces the completion of the first human dosing of ARGX-113, a potential breakthrough therapy for the treatment of autoimmune crisis. (more…)

Cristal Therapeutics starts clinical phase I trial with nanomedicine CriPec® docetaxel in patients with solid tumours

Date: 29/09/2015

29 September 2015, Maastricht, The Netherlands – Cristal Therapeutics, a privately-held life sciences company developing innovative drugs against cancer and other diseases, today announced the recent start of a clinical phase I trial with its lead candidate CriPec® docetaxel (more…)

arGEN-X’ partner RuiYi, Inc. announces first human dosing of gerilimzumab, a novel SIMPLE antibody™ against IL-6

Date: 23/09/2015

23 September 2015, Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) today reports that its partner RuiYi, Inc., a company focused on the discovery and development of novel biologic therapies (more…)

TheraSolve Announces US Patent Issuance for MemoPatch®

Date: 15/09/2015

15 September 2015, Diepenbeek, Belgium – TheraSolve NV, a medication adherence innovator, announced today patent issuance from the United States Patent and Trademark Office for its innovative MemoPatch® reminder technology. (more…)

NightBalance strengthens competitive position in sleep apnea market with key US and EU patent for innovative Sleep Position Trainer

Date: 19/08/2015

19 August 2015, Delft, the Netherlands – Today the European Patent office has granted NightBalance an important patent for their “method and device for sleep posture correction”, following the earlier grant by the US Patent and Trademark Office on July 30th 2015. (more…)

arGEN-X and University of Bern enter into license agreement

Date: 30/07/2015

30 July 2015, Breda, The Netherlands/Ghent, Belgium – arGEN-X and the Clinical Research Department of the University of Bern announce an exclusive license agreement enabling arGEN-X to develop and commercialize ARGX-110-based therapies to overcome treatment resistance mechanisms in hematologic tumors. (more…)

FABPulous wins €1.6m EU grant for clinical trials of 5 minute heart attack test

Date: 21/07/2015

20 July 2015, Maastricht (Netherlands) – The European Union awarded FABPulous BV a €1.6 million Phase 2 grant to fund two clinical trials in the UK and Belgium/Netherlands and automate the manufacture of its 5 minute, patented H-FABP True Rapid Test® (more…)

Cristal Therapeutics announces collaboration with PX Biosolutions to develop CriVac® based vaccines

Date: 14/07/2015

14 July 2015, Maastricht – Cristal Therapeutics, a privately-held life sciences company developing innovative products against cancer and other diseases, by using its patented nanotechnology platforms, today announced the start of a collaboration with PX Biosolutions (Melbourne, Australia). The joint research and development is focussed on the application of Cristal Therapeutics’ vaccine technology CriVac® for the design of innovative vaccines.

The CriVac® platform enables the tailor-made development of well-characterized polymeric nanoparticles of a specific size, that allow optimal antigen presentation to dendritic cells. CriVac® is one of the proprietary nanotechnology platforms of Cristal Therapeutics, next to CriPec®.

PX Biosolutions is an Australian based company operating from Melbourne, Victoria. PX Biosolutions’ scientists have developed DCtagTM vaccine formulations against various types of cancer. These vaccine formulations have been tested successfully in animal models.

NightBalance patent for “method and device for sleep posture correction” granted by US PTO

Date: 01/07/2015

1 July 2015, Delft, the Netherlands – NightBalance BV, a leading innovator of obstructive sleep apnea (OSA) technology, announced today that the U.S. Patent and Trademark Office has granted (more…)

TheraSolve wins Biomedica 2015 Award for best Medtech Innovation

Date: 10/06/2015

9 June 2015, Diepenbeek (Belgium)  – TheraSolve NV presented its MemoPatch® reminder technology at the European Life Sciences Summit Biomedica 2015 and has been elected by the members of the Biomedica Foundation Board as winner in the category Medtech. (more…)

arGEN-X presents preliminary efficacy and expanded safety data from Phase I trial of ARGX-111 at ASCO

Date: 31/05/2015

31 May 2015 – Breda, The Netherlands. arGEN-X N.V. (Euronext Brussels: ARGX) will present the results of a Phase I, first-in-human dose escalation study of ARGX-111, (more…)

Cristal Therapeutics announces formation of Scientific Advisory Board

Date: 22/05/2015

22 May 2015 – Maastricht, The Netherlands – Cristal Therapeutics today announced the appointments of Prof. Dr. Rob Liskamp, Prof. Dr. Twan Lammers, Prof. Dr. Alberto Gabizon, Dr. Maninder Hora and Dr. William Zamboni (more…)

arGEN-X and LEO Pharma enter into alliance to develop antibody-based treatments for skin conditions

Date: 21/05/2015

21 May 2015 – Breda, the Netherlands/Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) and LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, today announced an alliance (more…)

arGEN-X awarded €1.5 million IWT grant

Date: 19/05/2015

19 May 2015 – Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) today announced that it has received a € 1.5 million grant from the Institute for the Promotion of Innovation by Sciences and Technology in Flanders (IWT). (more…)

NightBalance receives coverage from largest Dutch healthcare payor Achmea for sleep apnea device

Date: 18/05/2015

18 May 2015, Delft, the Netherlands – NightBalance announced today that Achmea, the largest healthcare payor in the Netherlands covering 5 million lives, will reimburse its Sleep Position Trainer (SPT). (more…)

arGEN-X announces publication on therapeutic potential of antibody ARGX-115 in cancer immunotherapy

Date: 23/04/2015

23 April 2015 – Breda, The Netherlands – arGEN-X N.V. (Euronext Brussels: ARGX) today announced the publication of new data showing that the preclinical therapeutic antibody ARGX-115 blocks the activity of GARP, a novel immune checkpoint. (more…)

arGEN-x N.V. Announces Changes to the Board of Directors

Date: 14/04/2015

14 April 2015, Breda, The Netherlands – arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies (more…)

arGEN-X EXPANDS PRECLINICAL PIPELINE WITH ARGX-115 FOR CANCER IMMUNOTHERAPY

Date: 06/03/2015

4 March 2015 – Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) today announced that it has exercised its option to exclusively license a first-in-class, preclinical therapeutic antibody candidate, (more…)

Lonza and arGEN-X announce a license agreement for therapeutic antibodies

Date: 18/02/2015

18 February 2015, Breda, The Netherlands – Lonza, a global leader in biological manufacturing and arGEN-X N.V. announced today that they have entered into a new, multi-product commercial license agreement for the production of arGEN-X’s therapeutic antibodies. (more…)

FABPulous successfully closes series B funding round and begins commercial activities

Date: 04/02/2015

4 February 2015, Maastricht – Today FABPulous announced the successful closure of their €1.8m Series B funding round by undisclosed new investors as well as some of the current investors. (more…)

Therasolve closes a EUR 2.4M series A financing round

Date: 22/01/2015

21 January 2015, Diepenbeek, Belgium – TheraSolve NV announces that it has recently closed an “A” financing round accounting for a total investment of EUR 2.4 million. (more…)

Hemics successfully closes new financing round and obtains CE marking

Date: 09/01/2015

9 January 2015, Eindhoven, The Netherlands – Hemics announces today that it received CE marking required for commercial sales of its medical device, the HandScan, and closed a new investment round, welcoming new investor DFZ Participaties. (more…)

€6 million in new capital and new CEO for Cristal Therapeutics

Date: 15/12/2014

15 December 2014, Maastricht, The Netherlands  – Biopharmaceutical company Cristal Therapeutics has completed a new financing round of over €6 million (more…)

arGEN-X Announces Advancement of Therapeutic Antibody Alliance with Shire

Date: 11/12/2014

11 December 2014, Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. today announced that its partner Shire has exercised its option to advance into preclinical development one or more product candidates (more…)

arGEN-X Submits IND Application to Evaluate ARGX-110 in Waldenström’s Macroglobulinemia

Date: 03/11/2014

3 November 2014, Breda, The Netherlands / Ghent, Belgium – arGEN-X announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b/2 trial of ARGX-110 (more…)

Strategic Investment by SkylineDx in Cancer Vaccine Company DCPrime

Date: 29/10/2014

28 October 2014, Rotterdam & Leiden – SkylineDx, an innovative company in the field of genetic testing for blood cancers, announced today a strategic investment of an undisclosed sum in the Dutch cancer vaccine company DCPrime. (more…)

arGEN-X completes recruitment of first part of Phase 1 patient study

Date: 15/10/2014

15 October 2014 – Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) has completed enrolment of the first expansion cohort of 15 patients with CD70-positive hematological malignancies (more…)

ArGEN-X lists successfully on Euronext Brussels

Date: 10/07/2014

10 July 2014 – ArGEN-X N.V., a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces the successful completion of its Initial Public Offering (more…)

arGEN-X and The Leukemia & Lymphoma Society Partner on Treatment of Waldenström’s Macroglobulinemia

Date: 11/06/2014

10 June 2014, Breda, the Netherlands / Ghent, Belgium – arGEN-X today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study (more…)

arGEN-X enters into long-term strategic alliance with Shire Pharmaceuticals

Date: 04/06/2014

June 4, 2014. Ghent, Belgium/Breda, the Netherlands – arGEN-X today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals. (more…)

arGEN-X announces collaboration with Bayer

Date: 28/05/2014

28 May 2014, Breda, the Netherlands – arGEN-X announced today the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X’s SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies. (more…)

Hemics starts cost-effectiveness and efficacy HandScan study in rheumatoid arthritis

Date: 31/03/2014

31 March 2014, Eindhoven, the Netherlands – Hemics BV announces today a multi-center clinical study to evaluate the cost effectiveness and efficacy of its HandScan in tight control treatment of rheumatoid arthritis (RA). (more…)

arGEN-X starts Phase Ib expansion cohorts with ARGX-110, a novel anti-CD70 antibody, in cancer patients

Date: 13/01/2014

13 January 2014, Breda, The Netherlands / Ghent, Belgium – arGEN-X announces that it has advanced ARGX-110, a novel anti-CD70 antibody, into the safety and efficacy expansion part of its Phase Ib study. (more…)

arGEN-X receives two preclinical milestone payments under collaboration with Shire

Date: 13/01/2014

13 January 2014, Breda, the Netherlands / Ghent, Belgium – arGEN-X announces the attainment of two important success milestones in its SIMPLE Antibody™ research and product development collaboration with Shire. (more…)

Aratana Therapeutics Acquires Okapi Sciences NV

Date: 06/01/2014

6 January 2013, Kansas City, USA and Leuven, Belgium – Aratana Therapeutics, Inc. (Nasdaq: PETX) today announced, that it has acquired Okapi Sciences NV. (more…)

ARGX-110 meets translational development goals in Phase Ib cancer study

Date: 17/12/2013

17 December 2013, Breda, The Netherlands / Ghent, Belgium – arGEN-X announces that the dose-escalation part of a Phase Ib study (more…)

arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer

Date: 04/11/2013

4 November 2013, Breda, The Netherlands / Ghent, Belgium – arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). (more…)

arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B

Date: 04/11/2013

4 November 2013, Breda, The Netherlands / Ghent, Belgium – arGEN-X has raised EUR 5 million ($6.8 million) as an extension of its series B financing round (more…)

DCPrime and Janssen to collaborate on potential new therapy

Date: 03/10/2013

3 October 2013, Leiden, The Netherlands – Cancer vaccine company DCPrime BV today announced that it has entered into a research and optional license agreement with Janssen Pharmaceuticals, Inc. (more…)

ArGEN-X initiates clinical Phase IB study of ARGX-111 in cancer

Date: 17/09/2013

17 September 2013, Breda, the Netherlands, and Ghent, Belgium – arGEN-X announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody™ product to enter the clinic this year. (more…)

ArGEN-X identifies potent antibody antagonists against complex chonic pain target Nav1.7

Date: 12/09/2013

12 September 2013, Breda, the Netherlands and Ghent, Belgium – arGEN-X announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology. (more…)

Okapi Sciences enters into license agreement to develop & commercialise the world’s first antiviral veterinary drug

Date: 02/09/2013

22 August 2013, Leuven, Belgium – Okapi Sciences NV announces today that it has entered into an exclusive agreement with Novartis Animal Health for the joint development and commercialisation of an antiviral treatment for cats. (more…)

Argen-x grants licenses to its NHANCE™ antibody half-life extension technology

Date: 06/08/2013

August 6, 2013, Breda, the Netherlands – arGEN-X today announces the signing of its second non-exclusive license agreement for its antibody half-life extension technology, NHance™. (more…)

NightBalance closes new investment round to enable further growth

Date: 29/07/2013

29 July 2013, Delft – NightBalance today announced that it has closed a new investment round, welcoming new investor Van Herk Investments. (more…)

Cristal Therapeutics raises additional funding

Date: 01/07/2013

1 July 2013, Maastricht and Utrecht – Cristal Therapeutics, the new trade name of the Dutch nanomedicine company Cristal Delivery B.V., (more…)

Cristal Therapeutics appears in BioCentury

Date: 24/06/2013

24 June 2013, Maastricht – In the BioCentury issue of this week (Vol. 21 Issue 25) , Cristal Therapeutics (formerly known as Cristal Delivery) (more…)

DCPrime’s Phase I/IIa trial with dendritic cancer vaccine in AML meets all clinical endpoints

Date: 28/05/2013

28 May 2013, Leiden, the Netherlands – Cancer vaccine company DCPrime today announced the successful completion of its Phase I/IIa study in acute myeloid leukemia (AML). (more…)

arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders

Date: 24/04/2013

Breda, the Netherlands and Ghent, Belgium, April 24, 2013 – arGEN-X announces that it has progressed its second product candidate this year into formal preclinical development. (more…)

Hemics and DEMCON start HandScan development

Date: 22/04/2013

Eindhoven, the Netherlands, April 22, 2013 – Today, Hemics BV and DEMCON Advanced Mechatronics BV announce that they have started developing the HandScan into a commercial product. (more…)

Akeso Medical Imaging renamed Hemics

Date: 08/04/2013

Eindhoven, the Netherlands, April 5, 2013 – Akeso Medical Imaging BV announces today that as of this day the company has adopted a new name: Hemics BV. (more…)

Galapagos to start Phase 2a study with GLPG0974 in IBD patients

Date: 27/03/2013

Mechelen, Belgium; 27 March 2013 – Galapagos NV (Euronext: GLPG) announced today that GLPG0974, (more…)

arGEN-X announces preclinical development of ARGX-112 for dermatology

Date: 25/03/2013

Breda, the Netherlands and Ghent, Belgium March 25, 2013 – arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, (more…)

Enanta Pharmaceuticals Announces Pricing of Initial Public Offering

Date: 21/03/2013

21 March 2013, WATERTOWN, Mass. – Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the pricing of its initial public offering (more…)

FABPulous announces CE marking of novel rapid acute myocardial infarction triage test

Date: 12/03/2013

12 March 2013, Maastricht, The Netherlands – FABPulous, a diagnostics company specialized in rapid tests in whole blood, announced today the CE marking of its first diagnostic product, the H-FABP True Rapid Test, as an aid in the diagnosis of acute myocardial infarction (AMI). (more…)

arGEN-X expands its therapeutic antibody alliance with Shire

Date: 07/01/2013

January 7, 2013, Breda, the Netherlands, and Ghent, Belgium – arGEN-X is broadening its therapeutic antibody collaboration with Shire. (more…)

arGEN-X initiates Phase Ib study of ARGX-110 in cancer

Date: 07/01/2013

January 7 2013, Breda, the Netherlands, and Ghent, Belgium – arGEN-X announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, (more…)

Article on the NightBalance Sleep Position Trainer (Dutch)

Date: 15/12/2012

15 December 2012, Delft, The Netherlands – The journal “Tijdschrift voor Ergonomie” has published a full article on the innovative Sleep Position Trainer (more…)

arGEN-X announces grant of broad US patent covering its SIMPLE Antibody™ platform

Date: 06/12/2012

6 December 2012, Breda, the Netherlands, and Ghent, Belgium – arGEN-X has received its first Notice of Allowance from the United States Patent and Trademark Office (USPTO) in connection with a portfolio of patent filings related to its SIMPLE Antibody™ discovery platform. (more…)

Fabpulous launches new company website

Date: 22/11/2012

21 November 2012, Maastricht – Fabpulous has today launched its new website. The new site highlights both the innovative ultra-rapid plasma preparation technology as well as Fabpulous’ first product, (more…)

Enanta Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering

Date: 06/11/2012

6 November 2012, Watertown, Mass., USA – Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious (more…)

Cristal Delivery wins prize “Utrechtse Ster 2012”

Date: 31/10/2012

31 October 2012, Utrecht, The Netherlands – Cristal Delivery announced today that it has won the prize “Utrechtse Ster 2012″‘. The announcement (more…)